Company Profile

Angel Medical Systems Inc
Profile last edited on: 3/24/2023      CAGE: 45BN5      UEI: KDCFB5BERXN4

Business Identifier: FDA approved: implantable cardiac surveillance system
Year Founded
2001
First Award
2009
Latest Award
2015
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

40 Christopher Way Suite 201
Eatontown, NJ 07724
   (732) 542-5551
   info@angel-med.com
   www.angel-med.com
Location: Multiple
Congr. District: 04
County: Monmouth

Public Profile

Operational for over twenty years (2001-present) Angel Medical Systems has been long time organized around advancing life-sustaining patient care and the management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA approved labeling indicating the firm's Guardian System is safe and effective, management are dedicated to providing physicians, health systems, and allied health professionals with the required resources to help advance the standard of patient care. The firm's AngelMed GuardianĀ® is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS) including heart attacks. It is well understood that delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms -- such as chest pain -- are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one third of heart attacks having atypical or no symptoms.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $3,446,871
Project Title: Acute Ischemia Monitor Utilizing Subcutaneous Electrodes

Key People / Management

  David R Fischell -- Chief Executive Officer

  Gordie Nye -- Chief Executive Officer

  Andrew Taylor -- President and Chief Financial Officer

  Robert E Fischell -- Founder and Chairman

  Patricia Gizzi- Scinto -- Vice President Clinical Affairs

  Bruce Hopenfeld

  Steve R Johnson -- Vice President, Research & Development

  Daniel D Keenan -- VP Research and Design

  David L Keenan -- Chief Operations Officer

  Kimberly Mora -- Vice President Regulatory Affairs

  Patricia Scinto -- Vice President Clinical Affairs

Company News

There are no news available.